Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 8.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 23,078 shares of the company’s stock after selling 2,015 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Moderna were worth $2,724,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Hobbs Group Advisors LLC purchased a new position in shares of Moderna during the 4th quarter worth about $664,000. Illinois Municipal Retirement Fund raised its stake in Moderna by 22.1% during the first quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after purchasing an additional 9,360 shares during the period. Swedbank AB purchased a new stake in shares of Moderna during the 1st quarter valued at $3,315,000. Wellington Management Group LLP grew its stake in shares of Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after buying an additional 1,614,460 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Moderna during the 1st quarter worth $2,693,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00. Following the sale, the director now owns 2,284,015 shares in the company, valued at approximately $290,572,388.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 93,158 shares of company stock worth $11,167,312. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Down 3.4 %

MRNA stock opened at $65.69 on Monday. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The firm has a 50 day simple moving average of $90.07 and a 200-day simple moving average of $110.96. The company has a market capitalization of $25.18 billion, a P/E ratio of -4.19 and a beta of 1.67. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period last year, the business earned ($3.62) EPS. On average, equities research analysts predict that Moderna, Inc. will post -9.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on MRNA shares. Evercore ISI reissued an “in-line” rating and set a $120.00 price target on shares of Moderna in a research report on Thursday, June 27th. Piper Sandler decreased their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Bank of America dropped their target price on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research report on Friday, September 13th. Barclays reduced their price target on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research report on Monday, September 16th. Finally, HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective for the company in a research report on Wednesday, August 28th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $100.44.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.